D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses clinical efficacy with agents targeted for NRG1-fusion–positive non–small cell lung cancer.
FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC
Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
OncLive’s April Roundup of Key FDA Decisions in Oncology
Applying the Heterogeneous Approach From NSCLC to SCLC
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer